Friday, 9 May 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 9 May 2025
Ascott/Nuevo
Ascott/Nuevo
Splashing millions on meetings

Industry has ploughed more than $24.3 million into third party meeting sponsorships in just six months with four companies spending more than $2 million each.

Drug flood overwhelming HCPs
Cancer doctors struggle with the speed at which new treatments are launched and guidelines are updated
TODAY
PBS drug touts complete response
New data suggests the PD-1 inhibitor can trigger complete tumour clearance, particularly in one certain type of cancer
TODAY
Medscape
Medscape
Company grows leadership team
Three major internal promotions, a series of leadership changes plus a handful of jobs now up for grabs at this growing pharma
8 May
What downturn? Pharma is back
Despite talk of headwinds, 2024 was a good year for the pharma industry with revenues booming for just about everyone
8 May
How leaders can fix disengagement
Aussie executive coach describes disengagement as frightening and urges companies to equip people leaders with the right tools
7 May
Who's industry's 'Most Influential'?
It's one of the most prestigious recognitions in the world and this year two pharma employees have made the list
6 May
ADG PRIME
ADG PRIME
Latest Jobs
CEOs earn 200X more than staff
New analysis uncovers the boss-worker pay gap and also lifts the lid on the median salary across companies
8 May
Trump floats bad policy for Aust
After months of talking softly, reports of a policy move by Trump could see the industry look to wield a big lobbying stick
8 May
Amgen shields $324 million drug
Company demands documents relating to biosim's ARTG listing to launch potential patent infringement case
8 May
Access gap blows out to 676 days
New figures show the time patients must wait for access to medicines has ballooned to a disturbing 22 months
7 May
Migraine drug scores double win
First-ever study to demonstrate significant improvements in migraine and depressive symptoms with a single drug
7 May
New roles for ex-Minister, top exec
Familiar faces return to the industry spotlight in high-profile roles, among a string of job changes across pharma
7 May
Newcomer knocks out second rival
But after claiming victory, stocks rise then tumble as the market questions its power against the world's biggest drug
7 May
Seizure drug hits PBS in 5 months
Quick turn around for UCB's newcomer which was recommended by the PBAC ahead of TGA approval
6 May
Drugs notching double digit growth
How high can they go? After years at the top of the PBS ladder these drugs still posted impressive growth in Q1
6 May
Lilly re-enters ring with Sanofi
Watch this space as the PBS listing process restarts putting an expected blockbuster on a collision course with a market leader
6 May
Pharmac weighs big name drugs
Funding is on the table for cancer and other major diseases, as NZ continues to boost its medicine subsidies
6 May
Pharma spearheads climate fight
European ranking of companies reducing greenhouse gas emissions shows which pharmas are going green while increasing revenue
5 May
GSK hot on MSD's heels in cancer
Newly approved endometrial cancer indication to be considered by the PBAC later this week
5 May
Most wanted job perks revealed
Employment benefits are important to Aussie pharma employees with at least one new and interesting perk now on the radar
5 May
ADG aus Doc
ADG Aus Doc
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.